Red Light Therapy for Bladder Control: Could Light Help With Urinary Health?

A randomized, placebo-controlled trial involving 160 people with overactive bladder found that a skin-adhesive light device worn for 12 weeks reduced urge incontinence episodes more than a sham device. Results like this have made red light therapy for bladder control an increasingly interesting area of research.

Photobiomodulation (PBM), which uses red or near-infrared light to influence cellular activity, has been investigated in overactive bladder, urinary incontinence, and pelvic floor rehabilitation. The studies have used specialized devices, including adhesive patches, nasal applicators, and intravaginal lasers. Whether external home-use panels can produce comparable outcomes remains an important question.

Urinary continence depends on coordination. The bladder stores urine, the urethra and its sphincter hold it in, the pelvic floor muscles provide support, and nerve signals between the bladder, spinal cord, and brain decide when to hold and when to release. A disruption at any of these points can produce leakage or urgency.

Four patterns account for most cases:

• Stress urinary incontinence: leakage during coughing, sneezing, laughing, lifting, or exercise, when pressure on the bladder exceeds what the urethra can hold back.

• Urge urinary incontinence: leakage linked to a sudden urge to urinate that is hard to defer.

• Mixed urinary incontinence: a combination of stress and urge symptoms.

• Overactive bladder (OAB): a symptom complex built around urgency, usually with frequent urination and nighttime waking to urinate (nocturia), with or without urge incontinence.

Leakage does not always mean weak pelvic floor muscles. Nerve signaling, prostate conditions, childbirth, menopause, and medications can all contribute, and bladder control problems affect men as well as women. The underlying cause shapes the treatment, which is why the type of symptom matters when reading any therapy’s research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) offers a thorough overview of each type.

Red light therapy is the popular name for photobiomodulation. PBM delivers non-ionizing light, which lacks the energy to strip electrons from atoms the way X-rays do, to tissue in order to influence biological activity.

Two bands of light dominate the research. Red light generally refers to wavelengths of roughly 600 to 700 nanometers. Near-infrared sits beyond visible red, commonly around 700 to 1,100 nanometers in PBM studies. Tissues absorb these wavelengths differently, so a 610 nm device and an 808 nm device are not interchangeable.

The best-studied mechanism begins inside cells. Photoacceptors such as cytochrome c oxidase, an enzyme in the mitochondria, absorb the light. That absorption can alter mitochondrial activity, the production of adenosine triphosphate (ATP, the molecule cells use to store and transfer energy), oxidative signaling, and inflammatory pathways. The direction and size of these responses depend on wavelength, dose, tissue type, and treatment conditions. PBM does not raise ATP in every setting.

Delivery matters as much as biology. Skin, fat, and muscle scatter and absorb light, so light applied to the lower abdomen does not automatically reach the bladder at an effective dose. Deeper penetration also does not guarantee a better outcome. And PBM covers both low-level laser and LED sources, which differ in how they deliver light, so a result from one cannot simply be assigned to the other.

Photobiomodulation uses red or near-infrared light to influence biological activity in exposed tissues. Researchers are examining four proposed pathways that could connect this to bladder control:

1. Changes in mitochondrial activity and cellular energy production.

2. Modulation of cellular signaling and inflammatory responses.

3. Tissue responses involved in muscle function and repair.

4. Influence on the neural signaling that governs bladder activity.

These pathways give researchers several ways to investigate how PBM might influence bladder and pelvic floor function.

Bladder and pelvic tissues depend on steady cellular function. Smooth muscle in the bladder wall contracts and relaxes throughout the day, and the tissue around it constantly maintains itself. PBM’s influence on mitochondrial activity and cell signaling gives researchers a reason to look at these tissues. A cellular response is a starting point, though, and does not by itself predict a change in continence.

The pelvic floor muscles support the bladder, and their contraction helps close the urethra under pressure. Pelvic floor muscle training is a cornerstone of conservative incontinence care, so recent trials have tested PBM as an addition to training. The 2023 and 2026 trials covered below follow that design, which lets researchers see what light adds on top of exercise. 

Storing and emptying urine depends on constant communication between the bladder, spinal cord, and brain. In overactive bladder, urgency signals can arrive out of proportion to how full the bladder is, which makes neural signaling a logical target for PBM research. A 2024 pilot study of nasal near-infrared PBM, described below, explored this idea. 

Four human studies form the core of the evidence. They differ in device, application site, and population, so each is summarized by what it actually tested.

Hwang and colleagues ran a prospective, randomized, double-blind, placebo-controlled, multicenter Phase III trial, published in the International Urogynecology Journal. The 160 participants wore a skin-adhesive low-level light therapy device that delivered 610 ± 10 nm light to two abdominal acupuncture points. Sessions lasted 20 minutes, three times a day, for 12 weeks.

The active group had a larger reduction in urge incontinence episodes than the sham group, and more of its participants achieved a reduction of more than 50%. Urinary frequency and nocturia did not differ significantly between groups, so the benefit was specific to urge incontinence episodes.

Its randomized, placebo-controlled design and 160 participants make it one of the more substantial clinical studies of PBM for overactive bladder. The protocol belongs to one specific adhesive device and should not be read as a home regimen.

Bower and colleagues, writing in Bladder, tested the nerve signaling idea from an unexpected direction: near-infrared light applied through the nose. This exploratory pilot included a safety assessment and used a single-case experimental design. Researchers tracked participants repeatedly over time, comparing their results with their own baseline measurements.

They reported improvements in urinary frequency and in overactive bladder-related quality of life, with no adverse events during the small study.

The findings are preliminary. This was not a large randomized efficacy trial, and the authors called for further controlled research. Nasal delivery also differs from applying light to the lower abdomen or pelvic region. The study’s value is in showing that PBM’s possible effects on bladder symptoms are being explored through more than one route.

A randomized, double-blind, placebo-controlled trial in Lasers in Medical Science enrolled 22 women with urinary incontinence and compared two combinations. One group did pelvic floor strengthening exercises with active PBM. The other did the same exercises with sham PBM. The active treatment used an 808 nm infrared laser at vaginal application points.

The active PBM group improved in pelvic floor muscle strength and in quality-of-life measures. Because both groups exercised, the comparison isolates what the light added to rehabilitation.

The sample was small and the application internal, so the study is best read as preliminary support for testing PBM as an adjunct to pelvic floor rehabilitation.

Bezerra and colleagues published a randomized, controlled, blinded, three-arm trial in Climacteric. It enrolled women aged 45 to 65 who had been through natural menopause at least a year earlier, and it compared pelvic floor muscle training plus active PBM, training plus sham PBM, and training alone. Participants completed eight weeks of two 50-minute sessions per week.

Pelvic floor muscle pressure rose numerically more in the active PBM group, but the differences between groups were not statistically significant. Urinary function showed a clinically significant improvement compared with the sham PBM group, and sexual function scores differed with statistical significance between the active and sham groups.

The outcomes that moved were symptom-focused, while the muscle-pressure measure did not separate the groups. That gives future trials a specific question: whether light influences tissue health and symptoms more than raw muscle force.

The women in this trial were postmenopausal with genitourinary syndrome of menopause, so the findings do not extend to everyone with bladder control problems. More detail is available in our 2026 clinical trial on photobiomodulation and pelvic floor training.

The clinical studies used different tools, and the differences are central to interpreting the results.

External adhesive devices. The 2022 overactive bladder trial used a specialized skin-adhesive device worn at abdominal acupuncture points.

Nasal devices. The 2024 pilot delivered near-infrared light through the nose.

Vaginal and intravaginal devices. Pelvic floor and genitourinary studies, including the 2023 trial, have applied light with internal clinical methods.

External red light panels. Consumer panels treat broader body areas from a distance. Their optical characteristics, treatment area, and dose differ from those of the devices above.

These approaches differ not only in where light is applied but also in how much of it reaches the target tissue. That distinction matters when interpreting clinical results or asking whether they can inform the use of a different device.

Six factors influence how much light reaches the target tissue: wavelength, irradiance (the power reaching the tissue per unit area), fluence (the total energy delivered per unit area), exposure time, distance from the tissue, and application site. Changing any one can change the biological response, which is why the dosage and exposure time behind a result matter so much.

PBM is generally considered low risk when administered appropriately. Safety depends on the device, wavelength, dose, treatment site, and the person using it. The studies above reported few adverse events, and the 2024 pilot reported none, though these were small, supervised studies of specific devices.

Users should follow device instructions and any eye protection guidance. Consumer panels are designed for external use and should never be inserted into the vagina or urethra.

Individual health circumstances and medications can affect whether a particular light-based treatment is appropriate. Pregnancy, cancer treatment, a history of cancer in the treatment area, and photosensitizing medication are all reasons to seek individualized medical advice first.

Red light therapy is not a treatment for urinary tract infections. Blood in the urine, pelvic pain, or new changes in urination call for medical assessment.

Several approaches have a longer track record than any light-based treatment, and many people use them in combination.

Pelvic floor muscle training. Kegel exercises and supervised pelvic floor physical therapy strengthen the muscles involved in continence and improve their coordination. The NIDDK guide to Kegel exercises explains how to find and train the right muscles.

Bladder training. Timed urination and urgency-control techniques help many people with overactive bladder gradually extend the interval between trips.

Lifestyle adjustments. Fluid management, cutting back on bladder irritants such as caffeine, and treating constipation can reduce symptoms, though the right changes vary by person.

Medical treatment. Depending on the diagnosis, a clinician may recommend medication, medical devices, nerve stimulation, or a procedure. The NIDDK treatment overview and the AUA/SUFU 2024 overactive bladder guideline describe the options in detail.

Matching the approach to the cause starts with an evaluation. Self-diagnosing the type of leakage risks treating the wrong problem.

These findings give researchers several reasons to continue investigating photobiomodulation for urinary and pelvic health. Trials have reported fewer urge incontinence episodes, improved overactive bladder quality of life, and gains alongside pelvic floor rehabilitation, with early signals from several delivery routes.

Open questions remain about which applications work best, which patients benefit most, and whether results from specialized devices carry over to external panels. Controlled trials will answer them.

Pelvic pain, new urgency, blood in the urine, or any change in urinary patterns warrants a conversation with a healthcare professional to identify the cause.

Wavelength, dose, and delivery method shape PBM outcomes in many other areas, not only bladder health. Readers who want to see how these factors play out elsewhere can start with Lumaflex’s guide to red light therapy for pain relief or browse Lumaflex’s red and near-infrared devices. Lumaflex devices are not intended to treat bladder or pelvic conditions. 

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you experience urinary leakage, urgency, pelvic pain, or changes in urination, consult a qualified healthcare professional.

1. Hwang et al. (2022). Low-level light therapy for overactive bladder. International Urogynecology Journal. https://pubmed.ncbi.nlm.nih.gov/35389054/

2. Bower et al. (2024). Nasal photobiomodulation for overactive bladder symptoms, pilot research. Bladder. https://pubmed.ncbi.nlm.nih.gov/39539470/

3. Photobiomodulation combined with pelvic floor muscle strengthening in women with urinary incontinence: randomized, double-blind, placebo-controlled trial (2023). Lasers in Medical Science. https://pubmed.ncbi.nlm.nih.gov/38017192/

4. Bezerra et al. (2026). Photobiomodulation and pelvic floor training: randomized trial. Climacteric. https://pubmed.ncbi.nlm.nih.gov/42566226/

5. NIDDK. Bladder Control Problems (Urinary Incontinence). https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-control-problems

6. NIDDK. Treatments for Bladder Control Problems. https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-control-problems/treatment

7. NIDDK. Kegel Exercises. https://www.niddk.nih.gov/health-information/urologic-diseases/kegel-exercises

8. AUA/SUFU. 2024 Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. https://www.auanet.org/documents/Guidelines/PDF/2024%20Guidelines/OAB%202024%20Unabridgedv2.pdf

9. NIH/NICHD. Treatment of Pelvic Floor Disorders. https://www.nichd.nih.gov/health/topics/pelvicfloor/conditioninfo/treatment